- Home
- CATX vs PLX Comparison
CATX vs PLX Comparison
Compare CATX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- PLX
- Stock Information
- Founded
- CATX 1983
- PLX 1993
- Country
- CATX United States
- PLX United States
- Employees
- CATX N/A
- PLX N/A
- Industry
- CATX Medical/Dental Instruments
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATX Health Care
- PLX Health Care
- Exchange
- CATX Nasdaq
- PLX Nasdaq
- Market Cap
- CATX 239.0M
- PLX 204.9M
- IPO Year
- CATX N/A
- PLX 1998
- Fundamental
- Price
- CATX $2.73
- PLX $2.37
- Analyst Decision
- CATX Strong Buy
- PLX Strong Buy
- Analyst Count
- CATX 10
- PLX 1
- Target Price
- CATX $12.30
- PLX $15.00
- AVG Volume (30 Days)
- CATX 1.7M
- PLX 1.1M
- Earning Date
- CATX 11-10-2025
- PLX 11-13-2025
- Dividend Yield
- CATX N/A
- PLX N/A
- EPS Growth
- CATX N/A
- PLX N/A
- EPS
- CATX N/A
- PLX 0.08
- Revenue
- CATX $1,235,000.00
- PLX $61,948,000.00
- Revenue This Year
- CATX N/A
- PLX $14.53
- Revenue Next Year
- CATX N/A
- PLX $75.77
- P/E Ratio
- CATX N/A
- PLX $30.60
- Revenue Growth
- CATX N/A
- PLX 62.79
- 52 Week Low
- CATX $1.60
- PLX $1.14
- 52 Week High
- CATX $12.90
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CATX 35.35
- PLX 55.49
- Support Level
- CATX $2.85
- PLX $1.60
- Resistance Level
- CATX $3.15
- PLX $2.45
- Average True Range (ATR)
- CATX 0.47
- PLX 0.17
- MACD
- CATX -0.17
- PLX -0.02
- Stochastic Oscillator
- CATX 0.75
- PLX 79.38
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.